Christopher Benecchi - 03 Feb 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role: Chief Business Officer
Signature: /s/ Anne Marie Cook, as Attorney-in-Fact for Christopher Benecchi
Issuer symbol: SAGE
Transactions as of: 03 Feb 2023
Transactions value $: -$93,575
Form type: 4
Filing time: 07 Feb 2023, 15:10:45 UTC
Previous filing: 21 Jun 2022
Next filing: 15 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SAGE	Common Stock	Award	$0	+6,750	+10.73%	$0	7,379	03 Feb 2023	Direct	F1, F2
transaction	SAGE	Common Stock	Tax liability	-$93,575	-2,119	-28.72%	$44.16	5,260	03 Feb 2023	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On October 1, 2021, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 22,500 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on February 3, 2023, resulting in the vesting of the PSUs as to 6,750 shares.
F2	Reflects beneficial ownership balance which includes 414 shares purchased on June 30, 2022 and 215 shares purchased on December 31, 2022, each under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.